

2 **Name of Journal:** *World Journal of Gastroenterology*

Manuscript NO: 53686

Manuscript Type: MINIREVIEWS

Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors

Federico Piñero, Marcelo Silva, Massimo Iavarone

Abstract

During the last decades, further knowledge of hepatocellular carcinoma (HCC) molecular mechanisms has led to development of effective systemic treatments including tyrosine kinase inhibitors (TKIs) and immunotherapy. In this review, we describe first and second line systemic treatment options for advanced HCC. Several trials have evaluated new drugs for the treatment of HCC

Match Overview

1	Internet 43 words crawled on 13-Nov-2019 onlinelibrary.wiley.com	1%
2	Internet 35 words crawled on 06-Jan-2020 f6publishing.blob.core.windows.net	1%
3	Internet 31 words crawled on 18-Dec-2019 ascopubs.org	1%
4	Internet 21 words crawled on 22-Sep-2017 www.impactjournals.com	1%
5	Internet 19 words crawled on 30-Aug-2019 ro-journal.biomedcentral.com	<1%
6	Internet 14 words crawled on 12-Oct-2015 ilca2015.org	<1%
7	Internet 14 words crawled on 19-Mar-2020 www.esmo.org	<1%
8	Internet 13 words	<1%

国内版

国际版

Sequencing of systemic treatment for hepatocellular carc



ALL

IMAGES

VIDEOS

103,000 Results

Any time ▾

Second line systemic therapies for hepatocellular ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539398>

Aug 18, 2015 · Core tip: **Hepatocellular carcinoma** (HCC) is the main cause of death in patients with cirrhosis with an increasing incidence worldwide. Sorafenib is the choice therapy for advanced HCC. Since then no other molecule has been registered as **first-line** therapy in this setting and one more vacuum arises from the absence of molecules registered as **second-line** therapy for patients who ...

Cited by: 10

Author: Marcello Maida, Massimo Iavarone, Maur...

Publish Year: 2015

Evolving HCC Treatment Paradigm: Combinations and ...

<https://www.onclive.com/inside-oncology/update-on...> ▾

With that, it's been a pleasure, Nik, to share our clinical experience, particularly your insight on the **systemic treatment** of advanced HCC [**hepatocellular carcinoma**]. I hope our audience also ...

Patterns and challenges of treatment sequencing in ...

<https://onlinelibrary.wiley.com/doi/abs/10.1111/jgh.13761>

A total of 433 (26.9%) and 160 (9.9%) patients received a **second line** and **third line treatment** after recurrent or progressive disease. Patients with more than one **treatment line** were diagnosed at significantly earlier **disease stages** ($P < 0.001$).

Cited by: 9

Author: Martha M Kirstein, Nora Schweitzer, Ther...

Publish Year: 2017





103,000 Results Any time ▾

Second line systemic therapies for hepatocellular ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539398>

Aug 18, 2015 · Core tip: **Hepatocellular carcinoma** (HCC) is the main cause of death in patients with cirrhosis with an increasing incidence worldwide. Sorafenib is the choice therapy for advanced HCC. Since then no other molecule has been registered as first-line therapy in this setting and one more vacuum arises from the absence of molecules registered as **second-line** therapy for patients who ...

Cited by: 10 **Author:** Marcello Maida, Massimo Iavarone, Maur...
Publish Year: 2015

Systemic Treatment for Advanced Hepatocellular Carcinoma ...

<https://www.mdedge.com/jcomjournal/article/219583/...>

Zhu AX, Park JO, Ryoo B-Y, et al. Ramucirumab versus placebo as **second-line treatment** in patients with advanced **hepatocellular carcinoma** following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

Evolving HCC Treatment Paradigm: Combinations and Sequencing

<https://www.onclive.com/inside-oncology/update-on...>

With that, it's been a pleasure, Nik, to share our clinical experience, particularly your insight on the **systemic treatment** of advanced HCC [**hepatocellular carcinoma**]. I hope our audience also ...

Novel Second-Line Treatments for Hepatocellular Carcinoma ...

<https://www.hematologyandoncology.net/supplements/...>

Patients eligible for **second-line treatment** must have relatively good functional status and liver function to tolerate **systemic treatment**. Studies evaluating the benefit of **systemic treatment** have limited enrollment to patients with an Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2 and with Child-Pugh class A cirrhosis.


Patterns and challenges of treatment sequencing in ...

<https://onlinelibrary.wiley.com/doi/abs/10.1111/jgh.13761>

A total of 433 (26.9%) and 160 (9.9%) patients received a **second line** and **third line treatment** after recurrent or progressive disease. Patients with more than one **treatment line** were diagnosed at

Hepatocellular Carcinoma

Medical Condition



The most common form of liver cancer often seen in people with chronic liver diseases like cirrhosis.

- Rare (Fewer than 200,000 cases per year in US)
- May be preventable by vaccine
- Often requires lab test or imaging
- Treatment from medical professional advised
- Can last several months or years

Caused mainly due to the chronic infection of the liver or DNA mutation of the liver cells. Characterized by unexplained weight loss, upper abdominal pain and yellowing of the skin. Treatment options include hepatectomy, target drug delivery and the use of radiation to kill the cancerous cells.

Symptoms